Ocugen Inc - OCGN Net Assets per Single Share

Graphic logo of Ocugen, Inc. (OCGN)

Ocugen, Inc. (OCGN) operates by developing treatments for ocular pathologies, which entails high risks due to the lack of stable cash flow, with the indicator standing at -0.05. This price chart illustrates the performance of the company, whose developments are constrained by strict FDA oversight and costly patenting processes. Furthermore, global conflicts and sanctions significantly hinder the international logistics of biomaterials and the execution of joint research.

Ocugen Corp (OCGN) Equity per Share: for the period 07/04/2022 - 10/28/2026
Manufactured products of Ocugen

To protect the portfolio, fundamental screening utilizes the book value per share, calculated as the ratio of total equity minus intangible assets to the number of outstanding securities. In the case of Ocugen, Inc. (OCGN), this indicator reflects the capitalization of the startup's tangible resources, whose value depends on the success of gene therapies rather than market cycles, as confirmed by the share's book value data.

Competitor analysis

Book Value per Share TEM|QGEN: Book Value of One Share|Net Assets per Single Share Ionis Pharmaceuticals|repligen.com (RGEN) - Equity per Share|Book Value per Share Avidity Biosciences, Inc. (RNA)|Equity per Share CRSP|Net Assets per Single Share Sema4 WGS|Equity per Share Ultragenyx Corp (RARE)|Book Value per Share BEAM (Beam Therapeutics Inc.)|sarepta.com - Book Value per Share|TWST (Twist Bioscience, Inc.) - Net Assets per Single Share|TXG - Net Asset Value per Share|NTLA (Intellia) - Book Value per Share|Accounting Value per Share Stoke Corp|BLFS (BioLife Solutions, Inc.) - Accounting Value per Share|Book Value per Share wavelifesciences.com|MAZE: Book Value per Share|Book Value of One Share Sionna Therapeutics, Inc. (SION)|PRME: Book Value per Share|Taysha Corp - Net Asset Value per Share|uniQure N.V. (QURE) - Net Assets per Single Share|meiragtx.com (MGTX) - Equity per Share|Accounting Value per Share REGENXBIO RGNX|Solid Biosciences Inc (SLDB) - Accounting Value of a Share|PACB: Book Value per Share|Net Assets per Share BNTC|Net Assets per Single Share Design Therapeutics DSGN|Equity per Share rocketpharma.com (RCKT)|4D Molecular Therapeutics, Inc. - Book Value per Share|LXEO - Accounting Value per Share|Accounting Value per Share KRRO (Korro Bio, Inc)|EDIT: Net Assets per Share|Net Assets per Single Share SLN|ProQR Therapeutics (PRQR) - Net Asset Value per Share|Book Value per Share CDXS|Accounting Value per Share Sangamo Therapeutics Inc.|NAUT: Book Value per Share|Book Value of One Share MGX (Metagenomi Therapeutics)|DTIL - Net Assets per Single Share|Equity per Share Generation Bio Co GBIO|Boundless Bio (BOLD) - Book Value per Share|XCUR: Equity per Share|Net Assets per Single Share imunon.com|Phio Pharmaceuticals Corp. (PHIO) - Equity per Share|MBIO (Mustang Bio Inc) - Book Value per Share|Book Value per Share RNAZ|Bionano Genomics, Inc. - Net Assets per Single Share|Net Asset Value per Share Applied DNA Sciences Inc (APDN)|Bluebird Bio - Book Value per Share|IPA - Accounting Value per Share|Omega Therapeutics - Accounting Value per Share|OMIC - Book Value per Share|Book Value per Share RGLS (Regulus Therapeutics Inc.)|Syros Pharmaceuticals Inc. (SYRS) - Book Value of One Share|Book Value per Share TBIO (Codex DNA)|Net Asset Value per Share TCON|Net Assets per Single Share Unity Biotechnology UBX